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Background: Transaortic transcatheter aortic valve implantation (TAo-TAVI) is a recently developed approach that
provides an alternative delivery route for valve replacement in patients with vascular abnormalities or existing
comorbidities. While initial studies have shown the principal efficacy and safety, the real world effectiveness and
safety of this approach remains to be fully assessed.
Methods/Design: In this regard, the Registry Of the Utilization of the TAo-TAVI approach using the Edwards SAPIEN
Valve (ROUTE) represents the first multicenter, multinational prospective documentation of the course and outcome
of patients with severe calcific aortic stenosis (AS) undergoing TAo-TAVI. ROUTE commenced in February 2013 with
the goal of consecutively enrolling 300 patients at up to 22 sites across Europe. The primary objective of ROUTE is
to determine the 30-day mortality associated with TAo-TAVI using the Edwards SAPIEN THV (Edwards Lifesciences,
Irvine, CA). In addition, ROUTE aims to quantify complications, predictors of patient outcome and the value of CT
guided valve sizing.
Discussion: Findings from this landmark registry will provide important information regarding procedural success
rates and early mortality in patients undergoing TAo-TAVI.
Trial registration: Identifier: NCT01991431.
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Aortic stenosis (AS) is a disease characterized by progres-
sive narrowing of the aortic heart valve and is most
frequently caused by age-related calcification. At 75 years
of age 4.6% of the adult population displays severe AS
[1], and at 85 years old this prevalence increases to 8%
[2]. Thus, calcific AS represents the most common form
of valve disease in the Western world, constituting a
significant healthcare burden [1,3]. The 1-year and 5-year
survival rates for untreated patients with AS were re-
ported to be 62% and 32%, respectively [4].* Correspondence: peter.bramlage@ippmed.de
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unless otherwise stated.Therefore, severe symptomatic AS is considered to be a
class I indication for aortic valve replacement surgery [5], a
treatment that has demonstrated good efficacy and safety
[6,7]. Nevertheless, it has been suggested that 30–40% of
elderly patients are never offered surgical intervention
for AS due to advanced age, comorbidities and high sur-
gical risk [3,8]. In this regard, transcatheter aortic valve
implantation (TAVI) has emerged as a viable alternative
to conventional valve replacement in patients for whom
open heart surgery is not suitable [9]. For this reason, the
TAVI technique has gained popularity since it was first
described by Cribier et al. [10,11], yielding promising
clinical results over time [12-14]. In fact, a recent
randomized clinical trial revealed a 20% reduction in the
all-cause mortality associated with the use of TAVI inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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conventional surgery [15].
The Edwards SAPIEN transcatheter heart valves (THV)
(SAPIEN XT, SAPIEN 3) are commercially available de-
vices for performing TAVI, and can be introduced into the
body via transfemoral (TF), transapical (TA) or trans-
subclavian routes [12,13,16,17]. However, in some cases
TF and/or TA delivery are impossible due to anatomical
abnormalities or existing comorbidities (e.g., respiratory
disease or decreased left ventricular function). Therefore,
a primary goal related to refining such devices has been to
improve deliverability in order to reduce patient mortality
and morbidity. In this regard, transaortic (TAo) implant-
ation has been shown to be feasible and safe in patients
[18-20], and TAo delivery of Edwards SAPIEN valves was
recently approved in Europe. Nevertheless, the approach
remains to be evaluated, and further study is required to
fully assess the efficacy and applicability of the TAo-TAVI
procedure. Indeed, it remains unclear which patients may
show the most benefit or risk associated with TAo-TAVI.
The Registry Of the Utilization of the TAo-TAVI
approach using the Edwards SAPIEN Valve (ROUTE)
represents the first multicenter, multinational prospect-
ive study to investigate the course and outcome of
patients with symptomatic severe calcific AS undergoing
TAo-TAVI with the SAPIEN XT and SAPIEN S3 THVs.
ROUTE is an ongoing study, which commenced in 2013
to determine the 30-day mortality rate associated with
TAo-TAVI using Edwards SAPIEN XT and SAPIEN 3
THV. ROUTE should provide essential data regarding
procedural success rates and early mortality in patients
undergoing TAo-TAVI.
Methods/Design
The design of route
ROUTE is an international multicenter, prospective, ob-
servational registry with consecutive patient enrollment
at up to 22 sites across Europe. Ethical approval has been
obtained at the ethics committee responsible for each site
prior to patient enrollment. All patients are required to
provide written informed consent prior to study partici-
pation. The investigation commenced in February 2013.
The registry is registered at www.clinicaltrials.gov, Identi-
fier: NCT01991431.
Site selection
Sites are selected based on their TAo access experience
in different countries across Europe (France, Italy,
Netherlands, United Kingdom, Poland, Finland, Denmark,
Norway, Germany, and Austria). They are required to
have preliminary experience with TAo-TAVI (i.e., mini-
mum of five prior implantations).
Sites were, independent of this registry, trained in the
transaortic implantation of transcatheter heart valves inaccordance with the manufacturer’s instructions (Edwards
Lifesciences, Irvine, CA). Exhaustive fundamentals train-
ing was conducted (i.e., didactic sessions, case observa-
tions, device preparation, simulator training) along with
on-site training, which was consistent with the Edwards
Standard Operating Procedure.
Patients selection
Patients can be included in ROUTE if they display symp-
tomatic severe calcific AS and are scheduled to receive
TAo-TAVI using an Edwards SAPIEN THV (SAPIEN XT
or SAPIEN 3) irrespective of the feasibility of other
access routes. Also, subjects are required to present an
estimated operative/procedural mortality risk of ≥15% as
assessed by the Logistic EUROSCORE I or 10% STS-
PROM according to the IFU of the Edwards SAPIEN
THVs. However, patients showing any of the following
contraindications to the procedure are excluded from the
study: (1) congenital unicuspid/bicuspid aortic valves; (2)
evidence of an intracardiac mass, thrombus, vegetation,
active infection, or endocarditis; (3) inability to tolerate
anticoagulation/antiplatelet therapy; and/or (4) excessive
calcification of the aorta at the access site. In addition,
those patients receiving TAo-TAVI in combination with
another procedure (e.g., TAo-TAVI plus coronary artery
bypass graft) are excluded.
Enrollment and data collection
ROUTE aims at enrolling 200 consecutive patients at a
rate of approximately 2–3 subjects a month per site
(6–10 patients competitively enrolled per site). Patient
data must be collected at the time of valve implant-
ation (baseline), intervention, discharge, and 30 days
post procedure (i.e., ≥23 days and <37 days) (Table 1).
Complication rates are reported according to the Valve
Academic Research Consortium-2 (VARC 2) criteria [21].
Information is entered directly into a secure electronic
case report form (eCRF) by physicians or study nurses.
Notably, the eCRF was designed to perform automatic
checks for plausibility and completeness. Also, all correc-
tions are documented and tracked. Furthermore, 20% of
the sites are to be selected at random for monitoring and
source data verification after completion of patient docu-
mentation. In addition, 100% source data verification will
be conducted for the following serious adverse events:
death, stroke, major bleeding, valve complications, vascular
complications, permanent pacemaker implant, and renal
failure.
Pre-defined endpoints
The primary objective of ROUTE is overall mortality
within thirty days after TAo-TAVI. Secondary objective
are to determine TAVI related in-hospital and 30d
mortality, complication rates as to VARC 2 [21], the
Table 1 Data collection



















Current medications X X X
Interventional details X
Interventional results X
Adverse events X X X
Hospitalization duration X
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poor outcome of TAo-TAVI and to further establish role
of CT-technology in patient screening (valve sizing,
access planning, complication prevention).Statistics
The sample size for ROUTE was estimated based on an
overall mortality rate of approximately 7.1% at 30 days in
accordance with unpublished data provided by the prin-
cipal investigators. This rate can be ascertained with a
95% CI of 7.1 ± 3.56%. 95% confidence intervals are ±2.36
and ±3.02 at 3.0 and 5.0% risk respectively while they
are ±3.97 and ±4.34 at 9.0 and 11.0%.
Intent-to-treat analysis, defined as all patients enrolled
in the registry will be evaluated. Subjects are considered
registry participants when they enter the cath lab/hybrid
suite. Descriptive data summaries will be used to present
and summarize the collected evaluation data. For categor-
ical variables (e.g. gender) frequency distributions will be
given. For numeric variables (e.g. patient age) minimum,
maximum, mean, median and standard deviation will be
calculated.
Linearized rates and actuarial probability statistics will
be used when appropriate for adverse event reporting,
and Kaplan–Meier plots may be employed for survival
and outcome analyses.Amendments/Notes to file
The protocol which initially was confined to the docu-
mentation of the Edwards SAPIEN XT valve was opened
in February 2014 to allow the documentation of the
Edwards SAPIEN3 valve. In June 2014 the patient number
to be enrolled was increased by 100 resulting in a total of
300 enrolled patients and about 150 patients per valve.
Discussion
ROUTE represents the first multicenter, international
prospective registry to document the course and outcome
of patients undergoing TAo-TAVI with the SAPIEN XT
and SAPIEN 3 THVs. Thus, the findings from ROUTE
have the potential to contribute significant knowledge
regarding the clinical efficacy and applicability of the
TAo-TAVI procedure.
Available clinical data
Although recent reports have preliminarily suggested the
feasibility and safety of TAo-TAVI [18-20], the efficacy of
the procedure has not yet been completely established. In
a retrospective case study, Bapat et al. reported on 17 pa-
tients with severe AS who were implanted with Edwards
SAPIEN valves using TAo-TAVI because they were not
considered as candidates for the TA- and TF techniques
[18]. The outcomes of these subjects were subsequently
compared to those undergoing TA-TAVI. Even though
there was a higher prevalence of significant respiratory
disease in the patients treated with TAo-TAVI, 30-day
mortality rates were not significantly different for the
distinct delivery routes (11.8% for TAo-TAVI vs. 7.7%
for TA-TAVI; p = 0.577). Also, procedural complications
were reported to be similar for the two approaches.
Furthermore, Lardizabal et al. described 44 consecutive
patients undergoing TAo-TAVI for implantation of
Edwards SAPIEN valves [19], comparing their outcomes
to 76 subjects treated with TA-TAVI. Overall, similar
success rates and safety profiles were observed, with
all-cause death at the 30-day follow-up observed to be
14% for each. However, TAo-TAVI was associated with
lower combined bleeding/vascular event rates (27% vs.
46%; p = 0.05) and shorter median intensive care unit
hospitalization (3 vs. 6 days; p = 0.01).
More recently, Bapat et al. presented an overview of
more than 250 cases (10 centers; min. 4 cases) of which
158 had a complete dataset. Procedural success was high
(157/158 cases). All cause mortality was 7% (11/158),
5.1% had renal failure requiring dialysis, 2.5% PV leak of
at least grade 2 and 1.3% required reoperation due to
bleeding. Between January 2011 and February 2012
Romano et al. performed Tao-TAVI in 94 consecutive
patients with an unfavorable peripheral access for TF-
TAVI. Mean patient age was 84.1 ± 5.4 years (67-96) and
logistic Euroscore 17.6 ± 10.2%. The Sapien-XT valve was
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sternotomy allowed concomitant complete off-pump re-
vascularization (2-4 grafts) in 11 patients. Device success
rate was 92.6%. Paravalvular leak ≥2/4 was observed in
7.4%. Conversion to open chest surgery was required in
5.3% (3 aortic dissections, 1 valve migration, 1 left main
occlusion). Three cerebrovascular accidents (2 transient
ischemia and 1 delayed stroke) were noted. Transfusion
of ≥4 units was performed in 12 patients (12.8%). Inten-
sive care unit and total hospital stay were 4.9 ± 5.0 and
12.2 ± 6.2 days, respectively. Thirty-day mortality and
combined safety endpoint were reported in 7.4% and
14.9%, respectively.
Despite the fact that these initial studies yielded prom-
ising results, they were conducted using older delivery
systems that were not specifically designed for the TAo
route. In this regard, it was previously suggested that
lack of a dedicated TAo delivery system represented the
most important limitation associated with the TAo-TAVI
approach [19,20]. Therefore, findings related to 30-day
mortality rates and procedural complications in ROUTE,
will be important for determining the true safety and
efficacy associated with the TAo-TAVI procedure. Thus, it
is possible that improvements in patient outcome could be
observed in ROUTE when compared to previous investiga-
tions concerning TAo-TAVI.
Patient related outcome predictors
In addition to giving a clear picture of the overall mortality
and complication rates associated with performing TAo-
TAVI using the dedicated delivery system, ROUTE might
also allow for the identification of certain patient charac-
teristics that predict procedural success. Indeed, analysis
of multivariable adjusted predictors for poor outcome
after TAo-TAVI will be useful for determining optimal
patient profiles that are suitable for the TAo route. So far,
it has been proposed that TAo-TAVI represents an alter-
native procedure in individuals for whom the TA or TF
routes are not possible, such as patients with significant
respiratory disease, poor left ventricular function, chest
wall deformities, and/or multiple redo surgeries. However,
obtaining knowledge from a large population of patients
with severe AS will allow risk–benefit analysis to be
performed in distinct patient populations. In this regard,
the multicenter and international design of ROUTE will
facilitate the evaluation of diverse patients. Indeed, distin-
guishing contraindications for the TAo-TAVI approach
will be essential for optimizing safety and use of this tech-
nique in the future.
Transaortic delivery versus other access routes
TAo-TAVI was initially utilized when conventional
approaches were not possible. In some sites it has even
evolved, however, into a preferred approach in patientsnot undergoing TF-TAVI. It is even an alternative to TF-
TAVI in patients with a mobile atheroma in the arch
and/or a large atherosclerotic load in the descending
aorta with a possibility of embolism, because on can
avoid the instrumentation of the arch and descending
aorta [22].
With regard to the risks associated with the various
valve delivery routes, there is some evidence to support
the use of TAo-TAVI over TA-TAVI. Being a retrograde
approach, TAo-TAVI mimics TF-TAVI and is therefore
less invasive than the TA approach. Indeed, TA-TAVI
can lead to left ventricle tearing or rupture, which repre-
sents a critical and deadly complication that occurs in
2–6% of patients [23,24]. In addition, left-sided thoracot-
omy is required during TA-TAVI, which can result in
post-operative pain and respiratory issues [25]. It has
also been suggested that TA-TAVI might contribute to
decreased function of the left ventricle due to myocar-
dial damage induced by the procedure [26,27]. This data
will be important for establishing whether TAo-TAVI
represents a primary or secondary treatment option in
patients with severe AS. Indeed, it is possible that TAo-
TAVI performed using a dedicated system may represent
a safer alternative to the TA-TAVI approach.
CT based patient screening
While the analysis of outcomes and adverse reactions is
critical for examining the overall safety and efficacy of
TAo-TAVI in distinct patient cohorts, procedural plan-
ning also plays an essential role in treatment success.
For this reason, another objective of ROUTE is to fur-
ther assess the role of CT technology in patient screen-
ing (i.e., valve sizing, access planning, and complication
prevention). Indeed, studies have already begun to dem-
onstrate the utility of CT scanning for evaluating the
condition of aortic valves in patients with severe AS
[20,28]. Therefore, it is possible that CT technology
could be important for both procedural planning as well
as predicting outcomes based on anatomical consider-
ations. Taken together, assessment of the role of CT
technology in ROUTE might provide fundamental infor-
mation that could ultimately contribute to the improved
clinical care of patients with severe AS.
Potential limitations of route
ROUTE may display limitations related to the study
design. Indeed, there may be bias associated with site
selection, as participating hospitals have shown previous
interest in the TAo-TAVI procedure (i.e., requirement of
five prior implantations). However, this criterion is neces-
sary to ensure that the sites have sufficient experience in
TAo-TAVI to reduce the impact of technical complica-
tions on patient outcomes. Nevertheless, potential differ-
ences in expertise could allow for evaluation of possible
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less complete when compared to randomized clinical
trials. However, in this regard, 20% of the sites will be
selected at random for monitoring and source data verifi-
cation following completion of patient documentation.
Also, it is likely that the 30-day follow-up may not be
sufficient to truly evaluate adverse effects or patient out-
comes following TAo-TAVI. Thus, future assessment of
the long-term complications in AS patients undergoing
TAo-TAVI will be necessary in order to establish the
overall efficacy of this technique. Nevertheless, ROUTE
is an important step in evaluating patient outcomes after
TAo-TAVI.
Conclusions
The results of this registry will provide essential infor-
mation on procedural success rates and early mortality
in a large cohort of patients undergoing TAo-TAVI.
Therefore, completion of ROUTE represents an import-
ant step in assessing the early clinical efficacy and safety
of TAo-TAVI in patients with severe calcific AS.
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